tirzepatide phase 3 trial 80 weeks weight change retatrutide loss results Triumph-1 for and Tirzepatide once weekly for the

expounded on the obesity paradox, suggesting increased BMD is offset by poor bone quality due to advanced glycation end-products (AGEs) accumulation, impaired osteoblast function, and uncoupled bone turnover favoring resorption

Elevated growth hormone can support fat metabolism and muscle retention, but the evidence for meaningful fat loss in healthy adults is limited

This rare condition can cause sudden and typically permanent vision loss in one eye

Factors that may influence outcomes after discontinuation include the extent of lifestyle modifications implemented during treatment, baseline metabolic health, genetic factors, and psychosocial support systems